Exclusive: Novartis India Probes Sales Practices For Galvus; Heads Roll
This article was originally published in PharmAsia News
Executive Summary
PharmAsia News learns that Novartis India executives allegedly manipulated sales data and circumvented ethical trade practices to accelerate sales of diabetes therapy Galvus. Novartis has reportedly launched investigations and initiated remedial action.